Advanced Cell reports first data from stem cell trials

Advanced Cell Technology Inc. (OTCBB:ACTC) said the sub-retinal transplantation of human embryonic stem cell-derived retinal pigment epithelium (RPE) cells in two patients with ophthalmic disease showed no adverse safety issues and produced improvements in vision at four months following treatment. The data, published in The Lancet, were collected from a pair of open-label, U.S. Phase I/II trials. ...